Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

WastedTrader Jul. 8 at 12:24 AM

$CABA im still here! Not gonna lie, I hope this tanks below a dollar so I can buy 15k shares on the cheap 💪 stay strong bulls ✅️ long haul 💯, everyone wants to get rich quick, 15X your money in 2 years beats any common investment

0 · Reply

MarmotStock Jul. 7 at 11:42 PM

$CABA Next catalyst: 26-week durability read-out at ACR Convergence, 24 Oct 2025, and it is worth noting that biotechnology stocks often experience their squeezes 30 to 60 days in advance of such events. This is an important point to watch closely.

0 · Reply

Liveanddiebythethree Jul. 7 at 7:38 PM

$CABA when is this going to hit? Later this year? What’s the next anticipated catalyst.

1 · Reply

Yoety Jul. 7 at 7:12 PM

$CABA Big pile of poos, just dead money so far & it’s been for whiles now. F’n hard to hold!

0 · Reply

Moonman321 Jul. 7 at 5:45 PM

$CABA I know the way these money pigs work I worked in the industry Stock manipulation is a real thing They can play all the games they want This will take off. It’s just a matter of time. They’ll shake the tree as much as they can the undeserving will be left behind Don’t fight the fed Rate cuts incoming Small cap heaven

0 · Reply

ThomasTrainTrader Jul. 7 at 4:35 PM

$KYTX I don’t even say this to shit on $CABA as in the grand scheme of things it seems also undervalued, but I have yet to have anyone give me an answer as to why it is a better buy than Kyverna in any way, shape, or form other than the fact that it is a traditional meme stock that has more volume

1 · Reply

ThomasTrainTrader Jul. 7 at 4:30 PM

$KYTX Has enough cash to purchase the entire company of $CABA twice btw. Also has a more developed pipeline and leaders who have scaled manufacturing profitably. Yet is valued at $22 million less than CABA 😭

0 · Reply

Daydreamer8 Jul. 7 at 3:37 PM

$CABA bought🌈

0 · Reply

Moonman321 Jul. 7 at 3:25 PM

$CABA holding long on this one just snapped up a nice buy right here

0 · Reply

Moonman321 Jul. 6 at 5:37 PM

$CABA I decided one more $30,000 purchase tomorrow morning The upside on this is tremendous and will happen Don’t say those famous words I wish I would’ve bought more

1 · Reply

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 26 days ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 26 days ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 26 days ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 5 weeks ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 3 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 4 months ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 4 months ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 4 months ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 5 months ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 5 months ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 6 months ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 9 months ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 10 months ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 28, 2024, 8:00 AM EDT - 11 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 11 months ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 1 year ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 1 year ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 1 year ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 1 year ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 1 year ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 1 year ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 1 year ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 1 year ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 1 year ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

May 31, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 22, 2023, 4:30 PM EDT - 2 years ago

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023, 8:20 AM EDT - 2 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CYH EXAS MRNA NVAX ORGO PFE RARE

May 17, 2023, 10:16 PM EDT - 2 years ago

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 17, 2023, 4:01 PM EDT - 2 years ago

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 11, 2023, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 4:35 PM EDT - 2 years ago

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

Apr 27, 2023, 4:49 PM EDT - 2 years ago

Cabaletta Bio: Speculative Biotech With Opportunity

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

WastedTrader Jul. 8 at 12:24 AM

0 · Reply

MarmotStock Jul. 7 at 11:42 PM

0 · Reply

Liveanddiebythethree Jul. 7 at 7:38 PM

$CABA when is this going to hit? Later this year? What’s the next anticipated catalyst.

1 · Reply

Yoety Jul. 7 at 7:12 PM

$CABA Big pile of poos, just dead money so far & it’s been for whiles now. F’n hard to hold!

0 · Reply

Moonman321 Jul. 7 at 5:45 PM

0 · Reply

ThomasTrainTrader Jul. 7 at 4:35 PM

1 · Reply

ThomasTrainTrader Jul. 7 at 4:30 PM

0 · Reply

Daydreamer8 Jul. 7 at 3:37 PM

$CABA bought🌈

0 · Reply

Moonman321 Jul. 7 at 3:25 PM

$CABA holding long on this one just snapped up a nice buy right here

0 · Reply

Moonman321 Jul. 6 at 5:37 PM

$CABA I decided one more $30,000 purchase tomorrow morning The upside on this is tremendous and will happen Don’t say those famous words I wish I would’ve bought more

1 · Reply

Moonman321 Jul. 6 at 5:32 PM

$CABA no risk no reward 😆 Find my fourth round tomorrow it’s going be a good week

0 · Reply

MiroslavBroz Jul. 5 at 4:23 PM

$CABA Just so you know, CABA is also heard of in Croatia (4 million people)

0 · Reply

MiroslavBroz Jul. 5 at 4:18 PM

$CABA

0 · Reply

YasirTrades Jul. 5 at 3:26 AM

GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB

0 · Reply

MarmotStock Jul. 3 at 7:09 PM

$CABA CABA no longer faces any immediate dilution risk, as it has concluded its share issuance agreements. On the contrary, the company is approaching a significant catalyst, and it is worth noting that biotechnology stocks often experience their squeezes 30 to 60 days in advance of such events. This is an important point to watch closely!!! 🔨

1 · Reply

PeterMarksMD Jul. 3 at 6:45 PM

$CABA always the risk of more dilution.

2 · Reply

Drugtrade Jul. 2 at 6:37 PM

$CABA mc below cash, diverse pipeline.. tech is hit or miss. Put on short term 50/50 trade idea list. Would not add more than few 100 share to long port for now

0 · Reply